Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added; the page removed the government funding lapse notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding was added, informing users that information may not be up to date and transactions may not be processed, and that the NIH Clinical Center is open; the site version was updated to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page now shows the glossary and updates several metadata labels (e.g., Last Update Submitted that Met QC Criteria) with a new revision label v3.4.0, while some legacy labels and capitalization were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a new Locations section with California as a listed site and updated the revision from v3.3.2 to v3.3.3. The old California Locations link and the HHS Vulnerability Disclosure have been removed.SummaryDifference0.2%

- Check85 days agoChange DetectedThe page now displays a revision label 'Revision: v3.3.2' replacing the previous 'Revision: v3.3.1'.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.